cowtown jay
17 minutes ago
"Many public health professionals are convinced that a new serious variant of the original COVID-19 source, will eventually emerge through mutation. By the end of 2023, a total of 772 million people worldwide had contracted COVID and its variants, and a new milestone was passed — 7 million fatalities worldwide (over 1.2 million in the US).
As of this writing (April 2023), people continue to die each day from COVID-19 and its mutations. Source: World Health Organization
Only disciplined application of monoclonal antibody therapies has kept these numbers from being much larger.
When — not if — a new outbreak occurs, Taran will be among the first with the experience and resources to begin addressing that need quickly."
https://www.tarantherapeutics.com/the-opportunity
As an aside, I found this interesting. "In early 2024, Taran acquired the assets of Humanigen, a NASDAQ-listed company, through a bankruptcy sale. These assets included LENZ, which had already been developed at a cost of more than $500 million." This is the second reference I have seen to a number greater than half a billion dollars.
cowtown jay
55 minutes ago
For context: "the possibility of illegal bio-labs springing up across the country, and what could intentionally result from that, is a very, very real threat, and only serves to illustrate the great need we have for products like lenz." (oakhill3)
For context: "the possibility of illegal bio-labs springing up across the country, and what could intentionally result from that, is a very, very real threat, and only serves to illustrate the great need we have for products like lenz. (oakhill3)— Jay Booth (@booth37337) July 21, 2024
cowtown jay
1 day ago
eb, you and I know how the market reacted to news of our topline data. I've said several times that I sold shares in the $27 and $29 range on the day of that news, which merely anticipated that the news would garner regulatory authorization.
Now we know that the bankruptcy judge has reason to be assured that lenz will get approved, because of his approval of the amended APA in regards to Milestones.
Further, we see that the Black Horse entities were stuffed full of Humanigen shares, as I thought they would be. And I always believed that these shares were controlled by the company.
So Humanigen, which I think may still own the non-CAR-T patents,* and which also owns the vast majority of the OS, could see a billion dollars+ in profit if they merged before the shares were canceled, whether with Taran, or with the entity leveraging the Sanofi/Novavax co-exclusive licensing and commercialization partnership.
We're seeing cash balances for our zero shares in our Humanigen accounts. I think our shares are just teed-up ahead of our pending merger.
Thank you for your sustained encouragement. I'm so caught-up in the narrative I developed after these years of trying to understand the obstacles management has had to navigate around, that I have no patience for alternative explanations that just don't seem to fit (even if they are somehow right).
*https://www.plainsite.org/patents/assignment.html?id=11607371
cowtown jay
2 days ago
I mention the patented lenz cocktail with the non-mRNA vaccine (so, with the Novavax vaccine in the US), for a couple of reasons. Lenz has the capacity to improve the efficacy of the active treatment ingredient. Secondly, since deaths aren't caused by the virus, but rather by cytokine storm, lenz is the best product there is to control this hyper-inflammatory response.
As far as mentioning lenzilumab and vaccination in the same light, you're apparently ignorant of the patent which does just that.
METHODS FOR TREATING CORONAVIRUS INFECTION AND RESULTING INFLAMMATION-INDUCED LUNG INJURY
Publication number: 20230109208
Abstract: The present invention provides methods for treating a subject infected with 2019 coronavirus (SARS-CoV-2) comprising administering to the subject a therapeutically effective amount of a GM-CSF antagonist or a therapeutically effective amount of a GM-CSF antagonist and a second drug, including an anti-viral agent, an anti-SARS-CoV-2 vaccine, and serum containing human polyclonal antibodies to SARS-CoV-2.
Type: Application
Filed: March 8, 2021
Publication date: April 6, 2023
Applicant: HUMANIGEN, INC.
Inventors: Cameron DURRANT, Dale CHAPPELL
By the way, note the publication date of May 16, 2024, for Humanigen's patent regarding MATERIALS AND METHODS FOR TREATING CANCER.
MATERIALS AND METHODS FOR TREATING CANCER
Publication number: 20240158467
Abstract: This document provides methods and materials involved in treating cancer. For example, chimeric antigen receptor T cells having reduced levels of GM-CSF are provided. Also provided as methods for making and using chimeric antigen receptor T cells having reduced levels of GM-CSF.
Type: Application
Filed: March 15, 2022
Publication date: May 16, 2024
Applicants: HUMANIGEN, INC., MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH
Inventors: Cameron DURRANT, Dale CHAPPELL, Saad J. KENDERIAN, Michelle J. COX, Reona SAKEMURA
https://patents.justia.com/assignee/humanigen-inc
cowtown jay
2 days ago
"ArriVent Announces a Multi-Target ADC Collaboration with Alphamab
June 5, 2024"
https://ir.arrivent.com/news-releases/news-release-details/arrivent-announces-multi-target-adc-collaboration-alphamab
I wonder if former Board Member John Hohneker will facilitate the evaluation of Ifab as an ADC by ArriVent, where he is now on their Board. Management wants to use Ifab as an ADC, and ArriVent wants to develop new ADC candidates, so we could have a match. In fact, we already have promising clinical data regarding the use of Ifab to treat Glioblastoma multiforme (GBM), as I recall.
I'm also looking forward to hearing that another former Board Member, Kevin Xie, introduced the use of lenz in the greatly enhanced CAR-T platform used by Gracell, which has now become a subsidiary of AstraZeneca, where there are other applications for lenz and Ifab.
SorcererGuru44
2 days ago
I think Geoff took care of getting the HGEN shares, owned by Black Horse, converted to Taran. The Liquidating Trustee likely completed that process, along with the IP assignment for patents that were not already transferred to Taran.
If this were true it would have been in the Combined Plan in at least one of the many iterations that were submitted. But it wasn't.
When we stop bending words, every single thing we know as fact says you are just incorrect. I understand your hope, but please stop misleading people with untrue snippets of information.
cowtown jay
2 days ago
I think the ground work with Novavax and Sanofi is largely completed. I was a little worried when Filip's wife retired, and decided it was time for them to see the world and enjoy life. But none of Novavax's patents were for inventions by Filip. I think he was crucial to incorporating our lenz vaccine cocktail into their operation, but that was from the standpoint of his position as the President of Research and Development. Besides, he can enjoy life with his wife, and still help to integrate operations with Sanofi. He's been contributing remotely already, anyway.
But, that brings up the question of Humanigen's other patents for applications that were invented by Dale and Durrant. As I said earlier, I think Taran was only assigned three or four of Humanigen's patents, and they were all for CAR-T. I think Geoff took care of getting the HGEN shares, owned by Black Horse, converted to Taran. The Liquidating Trustee likely completed that process, along with the IP assignment for patents that were not already transferred to Taran. Whether this was done via a buyout, or via a merger, remains to be seen. Either way, it reunites our IP with our shares.
So, the above reflects my thoughts on issues that may be developing. I have more confidence in these developments, than I have in accepting that I have monetary value in my account, based on zero shares.
sosjtb
2 days ago
I’m showing a value in my account for my worthless shares, that value I assume is based on the last quoted price of just over a penny before it got kicked to the EM.
Your tenacity is great Jay and has given me hope for a rabbit trick, unfortunately they took everything and ran, I don’t see a rabbit in this hat. Good luck to you and your health.
If Lenz was actually worth more than $2million Durrant paid for it, logic says others would have gotten involved seeing it was being sold for next to nothing.
Nobody wanted it, Durrant basically absconded with it, Dale took our money.
US-JUSTICE
2 days ago
The corrupt judicial system in US was not always like this. over the years with cops, judges, and lawyers who are addicted to drugs. they take bribes for the money and cannot say no to drugs, mansions and cars. and since everybody is corrupt and doing crime. it's normal now. Look at Trump guilliani, and so many people who got screwed by the gov't or state. for political persecution. abusing the judicial system or corrupt judicial system. Like in Mexico, it becomes a failed state....when institutions no longer work or functioning. as it should. The justice dept unable to carry out justice or enforce justice. that is failed state. too much crime. overload. only 3% of crimes are solved kind of situation. or rampant stock fraud in the exchanges so SEC is failed institution.
SorcererGuru44
2 days ago
So you think a US BLA or regulatory approval, either domestically or internationally, which is required to activate a Milestone Event, is only worth pennies on the amount owed to Unsecured Creditors?
You've incorrectly merged multiple facts into one. I did not say that the milestones will pay off creditors in pennies on the dollar. I said the difference of keeping this CH11 and not 7 is fractions of a percent, aka pennies on the dollar. The whole process of not switching to 7 is cost of doing so, and the fact they structured the liquidation so creditors get at minimum what they would have in 7+ that fractional extra. I'm not sure why you believe the milestones will somehow equate to half a billion dollars to miraculously breathe life into a company that doesn't legally exist.
Just do the math they wrote in the docket for you.
cowtown jay
3 days ago
"As for the milestones, again, they are simply to pay off those creditors. Nothing more nothing less."
Nothing more?
So you think a US BLA or regulatory approval, either domestically or internationally, which is required to activate a Milestone Event, is only worth pennies on the amount owed to Unsecured Creditors?
Were you holding shares when our successful topline data was released from the LIVE-AIR trial? Even using your estimate of the company holding only 65% of the shares they issued, that could come to a whole lot of limbo moolah.
SorcererGuru44
3 days ago
I'm sorry but this is categorically false.
The statement you reference is simply in regard to CH11 obligations and paying off creditors. This is based on the fact that creditors will receive slightly more than they would had the company gone CH7. We're talking fractions of a percent, because that's all there is to offer. No further restructure needed is quite literally saying they won't be restructuring because they will not exist.
As for the milestones, again, they are simply to pay off those creditors. Nothing more nothing less.
Quite the opposite of your mention of "any financial recovery will be far greater than...", the recovery will be nowhere close to paying off creditors (whether it's real debt or not is another story). Not to mention, if they did somehow manage to pay off creditors it wouldn't matter as the company does not exist, and thus cannot be a debt free company.
It's repeated over 50 times in dockets I have linked and others in the epiq archive. No payout to shareholders is expected.
If your belief is so staunch that Taran is somehow magically pulling the whool over the eyes of the judge with clever phrasing, then why not believe what they wrote plain as day?
I more than anyone feel your pain in this Jay, but incorrectly identifying loopholes that aren't real is not some light at the end of the tunnel.
I stand with you on the benefits of Lenz, the potential lives saved, the money saved, the vast applications, even the trial results. But, we aren't talking about if the drug is good or not, we're talking about bankruptcy - and in this one we got bonked over the head.
There are no employees, the company is no longer in existence per the court, the shares have been deleted, the assets have been sold. No amount of belief or positive thinking can change that unfortunately.
Besides....email Durant and ask him yourself, then share the response with us. I all but listed his email in a previous post.
cowtown jay
3 days ago
I was getting around to this subject in a previous post.
""...the Debtor believes all chapter 11 plan obligations will be satisfied without the need for further reorganization of the Debtor. "
I can't reconcile the Debtor's statement, that all CH11 obligations will be satisfied, with your opinions that shareholders will be screwed. This is especially true since the Asset Purchase Agreement was amended to increase the number of Milestone Events, and also increase the amount of the payments for each Milestone Event. And we know that a US BLA, or regulatory approval from any of a number of foreign governments, are REQUIRED to reach a Milestone Event. For you guys to be correct about shareholders getting screwed, then the value from reaching the Milestone Events could not exceed the amount due to Unsecured Creditors. That will not happen, any financial recovery will be far greater than the amount owed to Unsecured Creditors."
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174714874
I think, rather than to believe that a debt-free company can go bankrupt, which Humanigen would be if a Milestone Event was reached, it's more likely that Taran either bought us out, or merged with us, before the shares were canceled.
cowtown jay
3 days ago
"What that means is that those shares were transferred to the Receiver of the Black Horse entities' assets, before they were canceled."
Is that why our non-existent, kaput, gone forever and ever, Amen, shares, reflect a monetary value in our account balances?
cowtown jay
3 days ago
I just look at nefarious intent through a different lens. I've done so since college, about 40 years ago, and the last half of those years were focused here and on one prior company.
I've shown the publications from Dale in the late 1990's, when he was a Howard Hughes Medical Institute fellow at the National Cancer Institute, where he studied tumor immunology and published in the field of T-cell therapy, immunology pathways, and granulocyte-macrophage colony-stimulating factor (“GM-CSF”), an immune system protein that initiates the cytokine storm that can occur in COVID-19. Here's a link once again to his co-publications.
https://www.researchgate.net/scientific-contributions/Dale-B-Chappell-33729906
Fast forward to the arrival of covid.
"Chappell’s world may seem remote from the COVID-19 units where some of his medical school classmates now struggle through harrowing days and nights. But with the advent of COVID-19, his path and theirs have converged: he is helping oversee (and fund) trials of a drug that may protect coronavirus patients from “cytokine storm” that can make the illness dire.
In some patients, cytokine signaling proteins that activate immunity go on overdrive, and the immune system goes haywire. The massive inflammation that results damages lungs and other organs. Patients need help breathing, and often they die.
Chappell’s fund, Black Horse Capital Advisors, has invested in a drug that appears to interrupt cytokine overproduction. Called lenzilumab (or “lenz”), the drug did well in a small case-control trial this spring. Twelve patients who were given lenz improved more quickly than did 27 controls. No one suffered a serious adverse effect...
Lenz has a three-year head start: with financing from Chappell’s fund, Humanigen had already explored its ability to prevent cytokine storm in organ transplant patients and in patients with refractory leukemia and lymphoma. Doctors now urgently need such a drug for a hugely expanded pool—people worldwide stricken by the novel coronavirus. Since February, says Chappell, “It’s been a lot of very early mornings and very late nights.”
https://dartmed.dartmouth.edu/2020/10/20/dale-chappell-med-99-mba/
The SEC and the health regulators may indeed be the winner here. They abuse their discretionary authority. The SEC is chartered to return disgorged money to the investors from whom it was stolen. But they don't. They transfer those funds to the US Treasury Dept. Shareholders, and their victimized companies, have their investment money stolen again, by the US government. And in this case...
that means millions people of people have, or will, suffer preventable deaths, either from covid, or covid-related indications, or covid vaccine-related indications. MILLIONS OF PEOPLE suffering preventable deaths, basically at the hands of unelected bureaucrats. Do you think any single one of them know more about lenzilumab's role in preventing cytokine storm, than our doctor/MBA management team?
I think, as do some researchers like Geert Vanden Bossche, that the worst of the pandemic is yet to come. See The_Inescapable_Immune_Escape_Pandemic.
Right or wrong, we need to be prepared. And right or wrong about a highly virulent form of the covid virus becoming a reality, we have got to rescind the discretionary authority of our government agencies, who play a large role in our pandemic history, as well as in the future we may very well face.
You can focus blame wherever you want, even if it is on the company and the management team that may well prove to be our salvation. But I'll continue to focus on reigning-in the rogue elements embedded in our government agencies, and I'll look forward to seeing them suffer the consequences of their corruption. After all, millions of lives hang in the balance.
SorcererGuru44
4 days ago
You make some very good points here, with exception to the 90% conclusion. I believe it was/is ( I say was because the shares no longer exist) around 65%.
I'm not necessarily one to disagree with the opinions you have about the testing itself. As I've always said, I'm a believer in the product. Unfortunately, I am not a believer in the management team we had.
Anyway. When it comes to scienter the fact is Dale had FDA communication that was not made available to investors and unloaded shares at a non-approved time with the knowledge nothing would get approved, while selling at a substantially lower rate than approved, with intent to "cover part of his mortgage" from the sale. This is after the CFO sounded alarm bells and said "we have a duty to update the market".
This is nail on the head territory for establishing bad faith.
cowtown jay
4 days ago
Truly, SG44, I appreciate your un-clouded perspective, and I think it is of significant value to the board.
But, as you know, I do not share your perspective.
I pinned my recent post regarding the possible company control of 90% of their issued shares because this was the first time I saw corroborating support, from the SEC, no less, of my conclusion. The Black Horse entities are stuffed to the gills with Humanigen shares, as I thought they would be. That can be argued, as can a lot of things. For instance, the District and Appellate Courts thought there was scienter based on an "inference" that there was a violation of the securities laws, and an asset freeze was ordered. But still, I haven't seen criminal charges filed by the DOJ. Lacking that DOJ action, an inference that a violation of securities laws may have been violated, is a pretty damn low bar to justify freezing the assets that were likely providing, in part, operating income for the company (such as by charging interest on the loaned shares).
Another unacceptably low bar is drawing a conclusion regarding lenzilumab's safety and efficacy, based solely of the SEC's opinion of how likely lenz was to be effective. I don't see any indication that the judge considered the Mayo Clinic case cohort study, or the results of the LIVE-AIR trial, or the Lancet peer-review, nor the Thorax peer-review, ALL of which demonstrated statistically significant, possibly game-changing efficacy. Other drugs were submitted for EUA's with similar, or smaller, trial sizes. In fact, the NIH trial, refuting the efficacy we claimed, had a smaller trial population than we had. In addition, the company made it clear that the the FDA wasn't the only regulatory agency to whom we submitted our LIVE-AIR results. I haven't seen anything from the MHRA saying they wanted to see a larger trial. So there was no reason not to copy both the FDA and the MHRA on our EUA applications, and NO nefarious intent should be ascribed to our management for doing so.
In addition, and especially with an asset freeze, management was faced with prioritizing their regulatory effort. This is a lot easier when management has partners, such as SAHMRI, Mayo Clinic, etc., who are conducting sponsored Investigator Initiated Trials (IITs). If regulatory approval of lenz can be obtained from these sponsored trials by our partners, it made sense not to follow the FDA's guidance to conduct another expensive company-sponsored trial.
I find the Third Circuit's decision largely devoid of serious merit. They claim, "The court noted that without the injunction, there was a substantial potential injury to Humanigen shareholders if Chappell was able to move assets out of reach of future judgment creditors." So, how much more could shareholders have been potentially injured, than we have been by this decision? There's no getting around the evidence, peer-reviewed in two different journals, that demonstrate the baseless FDA's projected determination of lenzilumab's safety and efficacy. Therefore, there can be no basis for a determination of scienter, at least not by management.
SorcererGuru44
4 days ago
The thing to remember here is that these are separate cases. One is the Humanigen bankruptcy case, the other is an SEC injunction against Dale & his entities. While there are some crossovers because of the participants, the information you referenced in the settlement agreement has no bearing on the SEC investigation. What the text suggests on 20/32 is nothing more than we will pay our creditors W from our insurance policy if they agree to not chase us with X, Y, or Z.
The latest filing in Yang v Durrant was nothing more than a change of attorneys for Buxton/Hohnecker/Cleary. The case is assigned to Judge William J. Martini and Magistrate Judge Andre M. Espinosa for all further proceedings, but as of now no updates.
To some of your specific questions:
- No criminal charges by DOJ I am aware of
- The charges wouldn't necessarily be outlined in the SEC filing because it's technically civil. What their intent is, is to show proof of wrongdoing in order to claim assets of whoever they are chasing. This would be no different than John Doe suing their neighbor because he borrowed $1000 and never returned it. The SEC just has more power and a different set of standards.
I've mentioned a couple of times the SEC's asset freezing and their use of the term disgorgement. Ultimately, we will not know what comes of it until there has been a resolution.
If you want my speculation - because Dale has tried to push against the overall basis of the asset freeze and failed, he will now beg for a hefty fine and promise to play good boy going forward. After all, he is now on a fixed (and I use that term loosely) income, and probably has hopes of recouping any of that ~50 million dollars. As the SEC points out on numerous occasions, he was spending excessively lavishly trying to milk as much as possible out of the freeze, and I see no reason he wont attempt to keep doing that. He thinks it's unfair it's even taking until October....but the SEC is in no hurry. I hope the SEC keeps the people damaged by their actions in mind, but even I find that unlikely.
cowtown jay
4 days ago
I've been looking for three exhibits that remain sealed, and I think it is safe to assume that they are in document ECF No. 23. Not that it mattes, sealed is sealed. But I spent a lot o time trying to find again where I saw that certain exhibits remained sealed.
Has the DOJ filed a criminal charge that you know of?
In terms of the information that was unsealed by the Appellate Court, I had another post that was in-process when your post was made. This is in regards to the charges, which were as follows.
""The Notice of Claims identified certain claims and causes of action against the Directors
and Officers, including, without limitation, (a) breaches of fiduciary duty; (b) aiding and abetting
breaches of fiduciary duty; (c) unjust enrichment; (d) aiding and abetting unjust enrichment; (e)
gross mismanagement; (f) insider trading; (g) waste of corporate assets; and (h) willful, reckless,
or negligent false and misleading statements or omissions of material fact with respect to (i) the
Debtor’s financial statements; (ii) the efficacy, safety and commercial viability of the Debtor’s
development drugs including lenzilumab; (iii) the efficacy of the Debtor’s internal controls; and
(iv) the failure to effectuate a value-accretive business combination with a privately held
biopharmaceutical company or additional financing on behalf of the Debtor (collectively, the
“Claims”)."
20/32
https://document.epiq11.com/document/getdocumentsbydocket/?docketId=1095423&projectCode=HUM&docketNumber=320&source=DM
Do you know if these charges were in the unsealed SEC filing, or just from the class action charges?
SorcererGuru44
4 days ago
The ticker hgenq is no longer even in the OTCmarkets.
True
there is no information on the status of the former ticker, nothing the ticker just 'vanished' from the exchange. Like phantom theif, they just take your money and disappear and never hear from them again kind of fraud. worse than being ripped in the flea market. and they call this GOV't regulated exchange too. NOT
False. It did not just vanish. This has been an ongoing process for 7 months and we knew it was going to happen. There is plenty of information available for anyone who wants to read it. Plus, as I mentioned in my last post....just contact your broker and ask them the status. It's not that hard.
How hard is it for management to write a 10 page sentence on status of company and post and upload in SEC site. no filings no notice on company website, no replies to emails from IR in company. and the ticker keeps trading.
There are plenty of updates by Epiq who is handling the bankruptcy, which has been posted many many times. They are easy to contact through that same website and are pretty responsive.
No schedule or information as to what happens to the ticker in people brokerage accounts, nothing no information whatsoever. in legal limbo as they say.
Legal limbo: Yes. But there is not a schedule because the liquidation is underway and brokerages don't have a crystal ball. To repeat myself one more time, call your brokerage and ask about ticker deletion and what their most recent ticker status update was.